FIELD: biotechnology.
SUBSTANCE: group of inventions relates to methods for creating a conditionally active chimeric antigenic receptor for binding to a target antigen selected from a tyrosine kinase growth factor receptor located on the surface of a cancerous cell of a solid tumour. Methods include conducting evolution of an antigen-specific targeting area in order to create a conditionally active antigen-specific targeting area with a reduction in the activity of binding the target antigen at a normal physiological pH compared with the activity of binding the same target antigen at an abnormal pH in the microenvironment of the tumour; and binding the conditionally active antigen-specific targeting area to a trans-membrane domain and an intracellular signalling domain in order to form a chimeric antigenic receptor. The conditionally active antigen-specific targeting area constitutes a multi-specific antibody evolved from a parent antibody or from a fragment thereof, or a conditionally active antigen-specific targeting area evolved from a parent protein or from a domain thereof.
EFFECT: conditionally active chimeric antigenic receptor is reversibly or irreversibly inactivated in the normal physiological condition for the wild type, but active under abnormal conditions in the microenvironment of the tumour.
19 cl, 14 dwg, 3 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS | 2015 |
|
RU2764074C2 |
METHODS AND FORMULATIONS FOR PRODUCING LYMPHOCYTES AND FOR CONTROLLED INCREASE THEREOF | 2017 |
|
RU2755059C2 |
CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
IMPROVED COMPOSITIONS BASED ON T-CELLS | 2015 |
|
RU2719030C2 |
ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2792042C2 |
CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
BIOMEDICAL CELL PRODUCT FOR TREATMENT OF MALIGNANT NEOPLASMS | 2023 |
|
RU2813531C1 |
METHOD OF PRODUCTION OF T-CELLS | 2015 |
|
RU2813668C2 |
Authors
Dates
2021-11-19—Published
2016-02-24—Filed